Role of Tissue-Type Plasminogen Activator in Remodeling of the Ductus Arteriosus

Junichi Saito, MD, PhD; Yoshihiro Ishikawa, MD, PhD; Utako Yokoyama, MD, PhD

Vascular remodeling (e.g., intimal thickening) is necessary for complete closure of the ductus arteriosus (DA). Smooth muscle cells are reported to contribute to DA remodeling. In contrast, the contribution of endothelial cells remains largely unknown. Recent data showed that tissue-type plasminogen activator (t-PA) was highly expressed in the endothelial cells of rat and human DA. It is well known that t-PA is an activator of the blood fibrinolytic system, but t-PA-induced localized proteolysis has been reported to play an important role in vascular development. We found that t-PA-induced plasminogen-plasmin conversion promoted matrix metalloproteinase-2 activation in endothelial cells of rat DA. Gelatinase activity was noted at the internal elastic laminae (IEL) of rat and human DA on in situ gelatin zymography. The in vivo injection of plasminogen to pre-term rats increased gelatinase activation, IEL disruption, and the subsequent intimal thickening formation in the pre-term rat DA. Human DA results partly supported the rat DA findings, suggesting that t-PA-mediated DA remodeling may also be present in the human DA. Current pharmacotherapy for patent DA (PDA) mainly focuses on increasing vascular constriction. Elucidating the molecular mechanisms of DA remodeling may help to expand the range of therapeutic strategies for PDA.

Key Words: Ductus arteriosus; Endothelial cell; Internal elastic laminae; Intimal thickening; Tissue-type plasminogen activator

The ductus arteriosus (DA) is a fetal blood vessel connecting the pulmonary artery and aorta, and is indispensable for maintaining fetal life. In utero, the DA diverts the right ventricular blood away from the high-resistance pulmonary circulation and into the systemic circulation where gas is exchanged with maternal blood. Closure of the DA is normally completed in the 3 days after birth, but pre-term infants often have a patent DA after birth. Persistent patent DA (PDA) occurs in more than half of pre-term infants,¹ and is related to blood flow imbalance (e.g., pulmonary congestion, and hypo-perfusion of systemic circulation) and subsequent mortality.^{2,3} Although approximately 50% of extremely pre-term infants receive pharmacotherapy with cyclooxygenase inhibitors, this involves a risk of renal dysfunction, spontaneous intestinal perforation and necrotizing enterocolitis.⁴ Thus, the current treatment strategies for PDA still need improvement.⁵

Complete closure of the DA involves 2 processes: functional and anatomical closure. Functional closure is a vasoconstriction induced by contraction of smooth muscle cells (SMC); anatomical closure is a form of vascular remodeling represented by intimal thickening.

Vasoconstriction of the DA

Postnatal DA constriction is triggered by increased arterial

pO₂, decreased blood pressure in the DA lumen, decreased circulating prostaglandin E₂ (PGE₂) level, and a decreased number of PGE₂ receptors.^{6–8}

The postnatal increase of pO₂ inhibits the ductal smooth muscle voltage-dependent potassium channels, such as Kv1.5 and Kv2.1,^{9,10} which causes membrane depolarization and calcium influx via the voltage-dependent calcium channels. This is followed by DA SMC contraction.¹¹ Voltage-dependent calcium channel and potassium channel genes are upregulated in the mature DA.^{12,13} In addition to calcium influx via voltage-dependent calcium channels, oxygen-induced activation of the Rho/Rho-associated coiled-coil containing protein kinase (Rho/ROCK) pathway is associated with postnatal DA constriction.¹⁴

Reduced circulating PGE₂ is related to postnatal DA constriction. The fetal DA is dilated by PGE₂, which is derived from the placenta.¹⁵ After birth, the loss of the placenta and the increased flow of the lung, which is the major site of PGE catabolism, cause a decline in circulating PGE₂.¹⁶ In addition, PGE₂ receptors are decreased after birth.¹⁷ These changes promote DA contraction.

Furthermore, we recently reported that serum osmotic change and glutamate are related to postnatal DA constriction.^{18,19} We found that premature infants did not have a physiological decrease in serum osmolarity after birth, and

Received February 21, 2020; accepted February 21, 2020; J-STAGE Advance Publication released online March 28, 2020

Cardiovascular Research Institute, School of Medicine, Yokohama City University, Yokohama (J.S., Y.I., U.Y.), Japan; Department of Cardiovascular Medicine, School of Medicine, Yale University, New Haven, CT (J.S.), USA; and Department of Physiology, School of Medicine, Tokyo Medical University, Tokyo (U.Y.), Japan

Mailing address: Utako Yokoyama, MD, PhD or Yoshihiro Ishikawa, MD, PhD, Cardiovascular Research Institute, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. E-mail: uyokoyam@tokyo-med.ac.jp (U.Y.) or yishikaw@med.yokohama-cu.ac.jp (Y.I.)

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cr@j-circ.or.jp

ISSN-2434-0790

Figure 1. Vascular remodeling of the ductus arteriosus (DA). **(A)** The human DA of a full-term infant shows prominent intimal thickening. Yellow lines, border of each layer. Scale bars, 1.0mm. **(B)** Schematic diagram of the developmental morphologic changes of the DA. ECM, extracellular matrix; IEL, internal elastic laminae.

Figure 2. Expression of tissue-type plasminogen activator (t-PA) in the ductus arteriosus (DA). **(A)** Rat (n=6) and **(C)** human (n=5) *Plat* mRNA expression on quantitative reverse transcription-polymerase chain reaction. **(B,D)** Elastica van Gieson staining to visualize elastic fibers (**Left**, dark purple) and immunohistochemical staining of t-PA in serial sections (**Right**, brown) in **(B)** rat DA on embryonic day 21 (scale bars, 100 μ m) and **(D)** human infant DA (scale bars: **Left**, 500 μ m; **Right**, 100 μ m). *P<0.05; **P<0.01. Reproduced with permission from Saito J, et al.⁴³

hypo-osmolality contributes to postnatal DA contraction via the transient receptor potential melastatin3 (TRPM3) channel, which is one of the osmotic sensors.¹⁸ We also found that the glutamate plasma concentration was decreased in human premature infants with PDA, and

that glutamate promoted the DA contraction through glutamate inotropic receptor α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate type subunit 1 (GluR1)-mediated noradrenaline production.¹⁹

Figure 3. Gelatinase activity in the ductus arteriosus (DA). **(A)** Schematic diagram of the activation of matrix metalloproteinase (MMP). t-PA, tissue-type plasminogen activator. **(B)** MMP activity in conditioned culture medium with rat DA endothelial cells and aortic endothelial cells (embryonic day 21). Active-MMP-2, 62 kDa; pro-MMP-2, 72 kDa; and MMP-9, 92 kDa. **(C,D)** Elastica van Gieson staining and in situ gelatin zymography of **(C)** rat DA on embryonic day 21 and **(D)** human DA. **(C)** High gelatinase activity (green) is seen in the internal elastic laminae (IEL; arrows), whereas ethylenediamine tetra-acetic acid (EDTA) supplementation inhibited the gelatinase activity (Nuclei, blue). Scale bars, 50 μ m. **(D)** High gelatinase activity is seen in the intimal thickening region and in the IEL. DQ-gelatin, Fluorogenic Dye-quenched gelatin. Scale bars, 200 μ m. Reproduced with permission from Saito J, et al.⁴³

Intimal Thickening of the DA

In addition to contraction of the DA, DA remodeling (e.g., intimal thickening) has been suggested to be essential for the complete closure of the DA.^{20–27} In human DA, intimal thickening occurs gradually in mid-gestation and becomes prominent at full term (**Figure 1A**). Intimal thickening is not complete in pre-term infants,^{27–29} and it is weakened in full-term infants with PDA.²⁶ The formation of intimal thickening in the DA involves some serial steps that occur toward birth (**Figure 1B**).²⁰ The disruption of the internal elastic lamina (IEL) and the detachment of endothelial cells from the IEL are the early steps in the formation of intimal thickening in the DA.²⁷ These processes are followed by the migration of SMC into the subendothelial region.^{27,28} PGE₂ receptor ‘EP4’ signaling then promotes the production of hyaluronan in the subendothelial region and the subsequent migration of SMC toward the DA lumen, resulting in intimal thickening.²¹ The role of SMC in DA remodeling is therefore important.

Disruption of the IEL

Disruption of the IEL is another hallmark of DA remodeling.^{28,30,31} The IEL of the DA is constructed similarly to the adjacent aorta in fetal development. Then, IEL disrupts

only in the DA in mid-gestation. In humans, the IEL disruption of the DA starts at approximately 17 weeks of gestation and becomes progressively obvious at 22–26 weeks of gestation.²⁷ The disruption of the IEL is followed by the migration of SMC into the subendothelial region, and intimal thickening becomes visible at the site of the disrupted IEL.^{28,29,32} Then, the IEL is disrupted more frequently between 27 and 34 weeks’ gestation,²⁷ and the further migration of SMC promotes narrowing of the DA lumen during late gestation. From these histological observations of human DA, the disruption of the DA IEL is suggested to be incomplete in pre-term infants born at <27 weeks of gestation, who often have PDA. Gittenberger-de Groot reported that human PDA tissue lacked IEL disruption and subsequent intimal thickening, while normal human DA tissue had this remodeling.²⁶

The functional role of the IEL as a barrier to the migration of SMC into the subendothelial region was also elucidated by using SMC- and endothelial cell-specific elastin knockout mice.³³ Lin et al demonstrated that IEL was derived from both SMC and endothelial cells, and that areas of neointimal hyperplasia correlated with local IEL disruption in the aorta.³³ In addition to the role of the IEL as a barrier to SMC migration, elastin itself affects the

Figure 4. Plasminogen-promoted internal elastic laminae (IEL) disruption, gelatinase activation and subsequent intimal thickening formation. **(A)** Schematic diagram of a 3-D model of vasculature. MMP, matrix metalloproteinase. **(B)** High gelatinase activity (green) is seen in the plasminogen-treated 3-D vascular model (**Upper panel**). Layered elastic fibers are seen on elastica van Gieson (EVG) staining (dark purple); this was disrupted in the plasminogen-treated 3-D vascular model (**Lower right**). Scale bars, 50 μ m. **(C)** Time course of the in vivo experiment. E, embryonic day; IT, intimal thickening. **(D)** Schematic diagram of the injection of plasminogen into the rat fetus. PBS, phosphate-buffered saline. **(E)** Plasminogen increased the gelatinase activity (**Upper**), and disrupted the internal elastic laminae (IEL; arrows) and increased the intimal thickening in the plasminogen-treated rat DA (**Lower**). Scale bars, 50 μ m. Reproduced with permission from Saito J, et al.⁴³

phenotype of vascular SMC. Mice with the global knockout of elastin have supravalvular aortic stenosis due to the accumulation of SMC,³⁴ and tropoelastin, which is a monomer of elastin, inhibits the proliferation and migration of SMC.³⁵

In our previous study, PGE₂-EP4 signaling prevented elastogenesis in the tunica media of the DA via the degradation of lysyl oxidase, which catalyzes elastin cross-links.³⁶ Unlike the sparse elastic fibers in the DA tunica media, IEL is first constructed and then progressively disrupted toward birth. Therefore, the signaling responsible for the disruption of the IEL is unclear.

Role of Endothelial Cells in the DA

Although we and others have reported that SMC have an important role in the formation of intimal thickening,^{21,22,37,38} the role of the endothelial cells adjacent to the IEL is largely unknown. DA endothelial cells contribute to the DA dilatation via the production of endothelial nitric oxide synthetase,³⁹ and endothelial cells also promote the proliferation of SMC and subsequent intimal thickening via the production of vascular endothelial growth factor.^{40–42} However, many points concerning the function of the DA endothelial cells are unclear. Recently, we found that endothelial cells play an important role in DA remodeling via the marked expression of tissue-type plasminogen activator (t-PA), which mediates matrix metalloproteinase-2 (MMP-2) activation, IEL disruption, and subsequent intimal thickening.⁴³ We herein introduce our recent findings.⁴³

Expression of t-PA in DA Endothelial Cells

We previously reported on the microarray analysis of rat DA and aorta,^{44,45} in which we found that t-PA was dominantly expressed in the endothelial cells of the DA.⁴⁴ We also confirmed the expression of t-PA on quantitative polymerase chain reaction using isolated DA endothelial cells and aortic endothelial cells from full-term rat fetuses (embryonic day 21).⁴³ In accordance with our previous microarray data, t-PA (*Plat*) mRNA was highly expressed in DA endothelial cells compared with aortic endothelial cells (**Figure 2A**).⁴³

We further examined the expression of t-PA in human DA.⁴³ Although RNA sequencing of the human DA was recently reported,⁴⁶ there has been no transcriptional profiling of the human DA intimal thickening region that contains DA endothelial cells. We collected human DA from neonatal patients with congenital heart disease and examined the expression of t-PA in the intimal thickening region compared with the tunica media. Although these patients had congenital heart disease, they required PGE₁ to maintain patency of the DA, and all DA had remarkable intimal thickening, suggesting that these DA had normally developed until sample collection. We found that the t-PA (*PLAT*) mRNA expression in the intimal thickening region was 3.6-fold higher than that in the tunica media (**Figure 2C**), and on immunohistochemistry for t-PA using rat and human DA, t-PA was markedly expressed in the endothelial cells of both the rat and human DA (**Figure 2B,D**).

It is well known that t-PA is an activator of the blood fibrinolytic system, but t-PA-induced localized proteolysis has been reported to play an important role in vascular development.⁴⁷ Levin et al investigated the developmental changes of locally expressed t-PA in the rat fetus and found that t-PA expression was dynamically regulated during vascular development.⁴⁷ On immunohistochemical staining

of t-PA using time-series rat fetuses, the t-PA was initially expressed in endothelial cells of the dorsal aorta and extended to the large arteries on embryonic day 13. The expression of t-PA was mostly decreased in the aortic endothelial cells by embryonic day 15. Alternatively, it appeared in the pulmonary, subclavian, vertebral and basilar arteries. After t-PA expression disappeared in the great arteries, t-PA expression was found in the smaller arterial branches.⁴⁷ The authors suggested that the primary function of locally expressed t-PA may be localized proteolysis to promote vascular remodeling during fetal development, rather than systemic vascular fibrinolysis.⁴⁷

Gelatinase Activity in the DA

t-PA converts plasminogen into plasmin,⁴⁸ which activates gelatinase MMP-2⁴⁹ and MMP-9;⁵⁰ and elastic laminae are mainly degraded by MMP-2 and MMP-9.⁵⁰ Our initial data showed the high expression of t-PA in DA endothelial cells of both rats and humans.⁴³ Thus, we aimed to elucidate whether DA endothelial cell-induced t-PA plays a role in disruption of the IEL through the activation of MMP.⁴³ We confirmed the gelatinase activity using isolated DA endothelial cells and aortic endothelial cells from rats (**Figure 3A**).⁴³ On gelatin zymography the pro-MMP-2 level in rat DA endothelial cells was higher than in aortic endothelial cells under basal conditions (**Figure 3B**, control).⁴³ Plasminogen supplementation increased MMP-2 activation in DA endothelial cells in comparison with aortic endothelial cells (**Figure 3B**, plasminogen). Neither DA endothelial cells nor aortic endothelial cells had detectable MMP-9 expression.⁴³ This suggested that the conversion of plasminogen to plasmin in DA endothelial cells promotes the activation of MMP-2.⁴³

Next, we confirmed the gelatinase activity in the DA tissue of rats and humans. In addition to gelatin zymography, prominent gelatinase activity was seen on in situ zymography in the intimal thickening region, which contains endothelial cells, and in the disrupted IEL of the DA (**Figure 3C,D**). This gelatinase activity was attenuated by the MMP inhibitor ethylenediamine tetra-acetic acid (EDTA).

Disruption of Elastic Laminae via MMP Activation

Although the t-PA-mediated activation of MMP is suggested to be involved in the remodeling of the vascular system,⁵¹ it is difficult to demonstrate the direct effect of t-PA on elastic laminae in vitro because cultured cells on a plastic plate cannot show the disruption of elastic fibers. We previously reported a 3-D vascular model that contains multilayered SMC and elastic laminae.^{52,53} In our recent study, we seeded endothelial cells on the top of the multilayered SMC and confirmed the effect of endothelial cell-derived t-PA on the layered elastic fibers (**Figure 4A**).⁴³ In untreated vascular models, layered elastic laminae were confirmed under endothelial cells (**Figure 4B, Left**). In contrast, supplementation of plasminogen (a substrate of t-PA) increased the gelatinase activation and the disruption of the elastic laminae (**Figure 4B, Right**). This gelatinase activation was attenuated by the MMP inhibitor EDTA. We also found that t-PA-targeted siRNA in endothelial cells attenuated the gelatinase activation and subsequent disruption of the elastic laminae.⁴³ These observations suggest that endothelial cell derived-t-PA involves the activation of MMP and subsequent disruption of elastic laminae.

In Vivo Plasminogen-Induced IEL Disruption and Intimal Thickening

A 3-D vascular model showed that plasminogen supplementation facilitated the disruption of elastic laminae via MMP activation. We then investigated whether plasminogen injection increased the IEL disruption and intimal thickening in the pre-term rat DA in vivo. On histology the IEL was almost completely intact on embryonic day 19 and became highly fragmented on embryonic day 21.⁴³ We also confirmed the high expression of t-PA in DA endothelial cells on embryonic day 19 on immunohistochemistry.⁴³ We then injected plasminogen on embryonic day 19 and analyzed the fetuses on embryonic day 20 (24h after injection; **Figure 4C**). We injected the plasminogen i.p. into rat fetuses (**Figure 4D**). In accordance with the 3-D in vitro vascular model, on in situ gelatin zymography the gelatinase was highly activated in the plasminogen-injected rat DA (**Figure 4E, Upper**). The IEL disruption and intimal thick-

ening were moderate and limited in controls (**Figure 4E, Lower left**). In contrast, the injection of plasminogen increased the elastic laminae disruption and the subsequent intimal thickening (**Figure 4E, Lower right**).

In our present study,⁴³ we were unable to measure the serum plasminogen concentration in rat fetuses due to the limited amount of serum, but it has been reported that human infants have lower blood plasminogen concentration than adults.^{54,55} Andrew et al reported that the serum plasminogen concentration in normal human full-term infants is 60% of that in adults,⁵⁴ and is lower in pre-term infants due to prematurity of liver function.⁵⁵ Furthermore, the activity of fetal plasmin was also lower than that of the adult type.⁵⁶ This indicates that infants physiologically have lower blood plasminogen level and plasmin activity; thus, the supplementation of plasminogen may help the t-PA-mediated IEL disruption in the DA.

Although plasminogen is associated with a possible unfavorable effect (bleeding tendency due to activation of fibrinolytic system), in clinical trials of plasminogen injection to premature infants, no apparent adverse effects were reported.⁵⁷ Before 1984, when surfactant therapy was started clinically for premature infants with respiratory distress syndrome (RDS),⁵⁸ several trials were performed to treat RDS infants, and one of those trials evaluated the effect of plasminogen on RDS. Pathologically, RDS is considered to be a hyaline-membrane disease. The hyaline membrane is composed of fibrin, which is derived from leaked fibrinogen from the pulmonary alveolus. This fibrin inhibits gas exchange and the activity of endogenous surfactant in the alveolus. Plasminogen was used to dissolve the fibrin of the alveolus in premature infants with RDS. Ambrus et al reported that the use of plasminogen in premature infants (1,000–2,500 g, at 28–40 weeks of gestation) decreased respiratory distress and mortality without obvious adverse effects in their double-blind, randomized clinical trials.⁵⁷ t-PA may promote IEL disruption of the DA without major adverse effects, but we must carefully consider the possibility of plasminogen injection in the treatment of premature infants with PDA.

Conclusions

Rat and human DA endothelial cells had high t-PA expression. Endothelial cell-derived t-PA facilitated IEL disruption through MMP-2 activation, which may aid in the formation of intimal thickening in the DA (**Figure 5**). The human DA results partly supported the rat DA results, suggesting that t-PA-mediated DA remodeling may also be present in human DA. The elucidation of the molecular mechanisms of DA remodeling may help to expand the range of treatment strategies for pre-term infants with PDA.

Acknowledgments

The authors are grateful to Toshihide Asou (Department of Cardiovascular Surgery, Kanagawa Children's Medical Center) and Munetaka Masuda (Department of Surgery, Yokohama City University) for providing human DA samples.

This work was supported by JSPS KAKENHI (J.S., JP18K15681, JP16H07107; U.Y., JP16H05358, JP15H05761, JP17K19403; Y.I., JP24390200, JP25670131), MEXT (Y.I., 22136009), and AMED (Y.I., 66890005, 66890011, 66890001, 66890023). These funders had no role in this study.

Data Availability

Data sharing is not applicable to this article given that no datasets

were generated or analyzed during the current study.

Disclosures

The authors declare no conflicts of interest.

IRB Information

Approval for the human study was obtained from the human subject committees at Yokohama City University (B150305001) and Kanagawa Children's Medical Center (1502-05). Approval for the animal study was obtained from the Institutional Animal Care and Use Committees of Yokohama City University (F-A-16-010).

References

- Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: Outcomes to discharge from hospital for infants born at the threshold of viability. *Pediatrics* 2000; **106**: 659–671.
- Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: A systematic literature review. *Acta Paediatr* 2012; **101**: 247–251.
- Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Host B, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. *Arch Dis Child Fetal Neonatal Ed* 2013; **98**: F505–F510.
- Benitz WE. Patent ductus arteriosus: To treat or not to treat? *Arch Dis Child Fetal Neonatal Ed* 2012; **97**: F80–F82.
- Hagadorn JI, Brownell EA, Trzaski JM, Johnson KR, Lainwala S, Campbell BT, et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. *Pediatr Res* 2016; **80**: 785–792.
- Clyman RI. Mechanisms regulating the ductus arteriosus. *Biol Neonate* 2006; **89**: 330–335.
- Yokoyama U, Minamisawa S, Ishikawa Y. Regulation of vascular tone and remodeling of the ductus arteriosus. *J Smooth Muscle Res* 2010; **46**: 77–87.
- Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. *Pharmacol Rev* 2013; **65**: 1010–1052.
- Michelakis E, Rebeyka I, Bateson J, Olley P, Puttagunta L, Archer S. Voltage-gated potassium channels in human ductus arteriosus. *Lancet* 2000; **356**: 134–137.
- Reeve HL, Tolarova S, Nelson DP, Archer S, Weir EK. Redox control of oxygen sensing in the rabbit ductus arteriosus. *J Physiol* 2001; **533**: 253–261.
- Nakanishi T, Gu H, Hagiwara N, Momma K. Mechanisms of oxygen-induced contraction of ductus arteriosus isolated from the fetal rabbit. *Circ Res* 1993; **72**: 1218–1228.
- Yokoyama U, Minamisawa S, Adachi-Akahane S, Akaike T, Naguro I, Funakoshi K, et al. Multiple transcripts of Ca²⁺ channel α 1-subunits and a novel spliced variant of the α 1C-subunit in rat ductus arteriosus. *Am J Physiol Heart Circ Physiol* 2006; **290**: H1660–H1670.
- Reese J, Waleh N, Poole SD, Brown N, Roman C, Clyman RI. Chronic in utero cyclooxygenase inhibition alters PGE₂-regulated ductus arteriosus contractile pathways and prevents postnatal closure. *Pediatr Res* 2009; **66**: 155–161.
- Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry G, Moudgil R, et al. Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: A newly recognized mechanism for sustaining ductal constriction. *Circulation* 2007; **115**: 1777–1788.
- Clyman RI, Mauray F, Roman C, Rudolph AM, Heymann MA. Circulating prostaglandin E₂ concentrations and patent ductus arteriosus in fetal and neonatal lambs. *J Pediatr* 1980; **97**: 455–461.
- Smith GC. The pharmacology of the ductus arteriosus. *Pharmacol Rev* 1998; **50**: 35–58.
- Bouayad A, Kajino H, Waleh N, Fouron JC, Andelfinger G, Varma DR, et al. Characterization of PGE₂ receptors in fetal and newborn lamb ductus arteriosus. *Am J Physiol Heart Circ Physiol* 2001; **280**: H2342–H2349.
- Aoki R, Yokoyama U, Ichikawa Y, Taguri M, Kumagaya S, Ishiwata R, et al. Decreased serum osmolality promotes ductus arteriosus constriction. *Cardiovasc Res* 2014; **104**: 326–336.
- Fujita S, Yokoyama U, Ishiwata R, Aoki R, Nagao K, Masukawa D, et al. Glutamate promotes contraction of the rat

- ductus arteriosus. *Circ J* 2016; **80**: 2388–2396.
20. Yokoyama U. Prostaglandin E-mediated molecular mechanisms driving remodeling of the ductus arteriosus. *Pediatr Int* 2015; **57**: 820–827.
 21. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaike T, Segi-Nishida E, et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. *J Clin Invest* 2006; **116**: 3026–3034.
 22. Yokoyama U, Minamisawa S, Quan H, Akaike T, Suzuki S, Jin M, et al. Prostaglandin E2-activated Epac promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A. *J Biol Chem* 2008; **283**: 28702–28709.
 23. Yokoyama U, Minamisawa S, Katayama A, Tang T, Suzuki S, Iwatsubo K, et al. Differential regulation of vascular tone and remodeling via stimulation of type 2 and type 6 adenylyl cyclases in the ductus arteriosus. *Circ Res* 2010; **106**: 1882–1892.
 24. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. *Biochem Biophys Res Commun* 1998; **246**: 7–12.
 25. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. *Nature* 1997; **390**: 78–81.
 26. Gittenberger-de Groot AC. Persistent ductus arteriosus: Most probably a primary congenital malformation. *Br Heart J* 1977; **39**: 610–618.
 27. Toda T, Tsuda N, Takagi T, Nishimori I, Leszczynski D, Kummerow F. Ultrastructure of developing human ductus arteriosus. *J Anat* 1980; **131**: 25–37.
 28. Tada T, Wakabayashi T, Nakao Y, Ueki R, Ogawa Y, Inagawa A, et al. Human ductus arteriosus. A histological study on the relation between ductal maturation and gestational age. *Acta Pathol Jpn* 1985; **35**: 23–34.
 29. Gittenberger-de Groot AC, van Ertbruggen I, Moulart AJ, Harinck E. The ductus arteriosus in the preterm infant: Histologic and clinical observations. *J Pediatr* 1980; **96**: 88–93.
 30. Jager BV, Wollenman OJ. An anatomical study of the closure of the ductus arteriosus. *Am J Pathol* 1942; **18**: 595–613.
 31. de Reeder EG, van Munsteren CJ, Poelmann RE, Patterson DF, Gittenberger-de Groot AC. Changes in distribution of elastin and elastin receptor during intimal cushion formation in the ductus arteriosus. *Anat Embryol (Berl)* 1990; **182**: 473–480.
 32. De Reeder EG, Girard N, Poelmann RE, Van Munsteren JC, Patterson DF, Gittenberger-De Groot AC. Hyaluronic acid accumulation and endothelial cell detachment in intimal thickening of the vessel wall: The normal and genetically defective ductus arteriosus. *Am J Pathol* 1988; **132**: 574–585.
 33. Lin CJ, Staiculescu MC, Hawes JZ, Cocciolone AJ, Hunkins BM, Roth RA, et al. Heterogeneous cellular contributions to elastic laminae formation in arterial wall development. *Circ Res* 2019; **125**: 1006–1018.
 34. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. *Cell* 1993; **73**: 159–168.
 35. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, et al. A critical role for elastin signaling in vascular morphogenesis and disease. *Development* 2003; **130**: 411–423.
 36. Yokoyama U, Minamisawa S, Shioda A, Ishiwata R, Jin MH, Masuda M, et al. Prostaglandin E2 inhibits elastogenesis in the ductus arteriosus via EP4 signaling. *Circulation* 2014; **129**: 487–496.
 37. Wu JR, Yeh JL, Liou SF, Dai ZK, Wu BN, Hsu JH. Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells through the Notch3-HES1/2/5 pathway. *Int J Biol Sci* 2016; **12**: 1063–1073.
 38. Kemmotsu T, Yokoyama U, Saito J, Ito S, Uozumi A, Nishimaki S, et al. Antenatal administration of betamethasone contributes to intimal thickening of the rat ductus arteriosus. *Circ J* 2019; **83**: 654–661.
 39. Clyman RI, Waleh N, Black SM, Riemer RK, Mauray F, Chen YQ. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: The role of gestation, oxygen tension, and vasa vasorum. *Pediatr Res* 1998; **43**: 633–644.
 40. Clyman RI, Seidner SR, Kajino H, Roman C, Koch CJ, Ferrara N, et al. VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. *Am J Physiol Regul Integr Comp Physiol* 2002; **282**: R199–R206.
 41. Clyman RI, Chan CY, Mauray F, Chen YQ, Cox W, Seidner SR, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: The roles of postnatal constriction, hypoxia, and gestation. *Pediatr Res* 1999; **45**: 19–29.
 42. Waleh N, Seidner S, McCurnin D, Giavedoni L, Hodara V, Goelz S, et al. Anatomic closure of the premature patent ductus arteriosus: The role of CD14+/CD163+ mononuclear cells and VEGF in neointimal mound formation. *Pediatr Res* 2011; **70**: 332–338.
 43. Saito J, Yokoyama U, Nicho N, Zheng YW, Ichikawa Y, Ito S, et al. Tissue-type plasminogen activator contributes to remodeling of the rat ductus arteriosus. *PLoS One* 2018; **13**: e0190871.
 44. Liu NM, Yokota T, Maekawa S, Lu P, Zheng YW, Taniguchi H, et al. Transcription profiles of endothelial cells in the rat ductus arteriosus during a perinatal period. *PLoS One* 2013; **8**: e73685.
 45. Yokoyama U, Sato Y, Akaike T, Ishida S, Sawada J, Nagao T, et al. Maternal vitamin A alters gene profiles and structural maturation of the rat ductus arteriosus. *Physiol Genomics* 2007; **31**: 139–157.
 46. Yarbboro MT, Durbin MD, Herington JL, Shelton EL, Zhang T, Ebby CG, et al. Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing. *Semin Perinatol* 2018; **42**: 212–220.
 47. Levin EG, Banka CL, Parry GC. Progressive and transient expression of tissue plasminogen activator during fetal development. *Arterioscler Thromb Vasc Biol* 2000; **20**: 1668–1674.
 48. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. *Cell Mol Life Sci* 1999; **56**: 104–132.
 49. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. *J Cell Physiol* 2002; **192**: 160–170.
 50. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. *Thromb Haemost* 2001; **86**: 324–333.
 51. Kruithof EK, Dunoyer-Geindre S. Human tissue-type plasminogen activator. *Thromb Haemost* 2014; **112**: 243–254.
 52. Ishiwata R, Yokoyama U, Matsusaki M, Asano Y, Kadowaki K, Ichikawa Y, et al. Three-dimensional multilayers of smooth muscle cells as a new experimental model for vascular elastic fiber formation studies. *Atherosclerosis* 2014; **233**: 590–600.
 53. Matsusaki M, Kadowaki K, Adachi E, Sakura T, Yokoyama U, Ishikawa Y, et al. Morphological and histological evaluations of 3D-layered blood vessel constructs prepared by hierarchical cell manipulation. *J Biomater Sci Polym Ed* 2012; **23**: 63–79.
 54. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. *Am J Pediatr Hematol Oncol* 1990; **12**: 95–104.
 55. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. *Blood* 1988; **72**: 1651–1657.
 56. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics: Correlation with increased glycosylation of the protein. *J Clin Invest* 1990; **86**: 107–112.
 57. Ambrus CM, Choi TS, Cunnanan E, Eisenberg B, Staub HP, Weintraub DH, et al. Prevention of hyaline membrane disease with plasminogen: A cooperative study. *JAMA* 1977; **237**: 1837–1841.
 58. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. *Lancet* 1980; **1**: 55–59.